Cargando…

Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis

Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Bergeron, A, Godet, C, Chevret, S, Lorillon, G, Peffault de Latour, R, de Revel, T, Robin, M, Ribaud, P, Socié, G, Tazi, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091913/
https://www.ncbi.nlm.nih.gov/pubmed/23208317
http://dx.doi.org/10.1038/bmt.2012.241
_version_ 1783510078105583616
author Bergeron, A
Godet, C
Chevret, S
Lorillon, G
Peffault de Latour, R
de Revel, T
Robin, M
Ribaud, P
Socié, G
Tazi, A
author_facet Bergeron, A
Godet, C
Chevret, S
Lorillon, G
Peffault de Latour, R
de Revel, T
Robin, M
Ribaud, P
Socié, G
Tazi, A
author_sort Bergeron, A
collection PubMed
description Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition.
format Online
Article
Text
id pubmed-7091913
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70919132020-03-24 Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis Bergeron, A Godet, C Chevret, S Lorillon, G Peffault de Latour, R de Revel, T Robin, M Ribaud, P Socié, G Tazi, A Bone Marrow Transplant Article Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition. Nature Publishing Group UK 2012-12-03 2013 /pmc/articles/PMC7091913/ /pubmed/23208317 http://dx.doi.org/10.1038/bmt.2012.241 Text en © Macmillan Publishers Limited 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Bergeron, A
Godet, C
Chevret, S
Lorillon, G
Peffault de Latour, R
de Revel, T
Robin, M
Ribaud, P
Socié, G
Tazi, A
Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title_full Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title_fullStr Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title_full_unstemmed Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title_short Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
title_sort bronchiolitis obliterans syndrome after allogeneic hematopoietic sct: phenotypes and prognosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091913/
https://www.ncbi.nlm.nih.gov/pubmed/23208317
http://dx.doi.org/10.1038/bmt.2012.241
work_keys_str_mv AT bergerona bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT godetc bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT chevrets bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT lorillong bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT peffaultdelatourr bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT derevelt bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT robinm bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT ribaudp bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT socieg bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis
AT tazia bronchiolitisobliteranssyndromeafterallogeneichematopoieticsctphenotypesandprognosis